In order to better evaluate the efficacy of TACE treatment for HBV-HCC, a focused riskScore was constructed based on five core indicators, with the riskScore formula= 0.082411012 * IL8 + 0.293025556 * Gal9 + 0.033152133 * TNFRSF4 + 0.014714986 * CD4+TIGIT+PD1+T cells + 0.045277334 * CD8+TIGIT+TIM3+T cells. The gene discussed is HAVCR2; the disease is hepatocellular carcinoma.